Is a prostate cancer screening anxiety measure invariant across two different samples of age-appropriate men?

BMC Med Inform Decis Mak. 2012 Jun 8:12:52. doi: 10.1186/1472-6947-12-52.

Abstract

Background: In order to explore the influence of anxiety on decision-making processes, valid anxiety measures are needed. We evaluated a prostate cancer screening (PCS) anxiety scale that measures anxiety related to the prostate-specific antigen (PSA) test, the digital rectal examination (DRE), and the decision to undergo PCS (PCS-D) using two samples in different settings.

Methods: We assessed four psychometric properties of the scale using baseline data from a randomized, controlled decision aid trial (n = 301, private clinic; n = 149, public).

Results: The 3-factor measure had adequate internal consistency reliability, construct validity, and discriminant validity. Confirmatory factor analyses indicated that the 3-factor model did not have adequate fit. When subscales were considered separately, only the 6-item PCS-D anxiety measure had adequate fit and was invariant across clinics.

Conclusions: Our results support the use of a 6-item PCS-D anxiety measure with age-appropriate men in public and private settings. The development of unique anxiety items relating to the PSA test and DRE is still needed.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Analysis of Variance
  • Anxiety / diagnosis
  • Anxiety / psychology*
  • Decision Support Techniques
  • Discriminant Analysis
  • Factor Analysis, Statistical
  • Humans
  • Male
  • Mass Screening / psychology*
  • Mass Screening / statistics & numerical data
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms / diagnosis*
  • Psychometrics / instrumentation*
  • Reproducibility of Results
  • Socioeconomic Factors
  • Surveys and Questionnaires
  • Texas

Substances

  • Prostate-Specific Antigen